APA (7th ed.) Citation

Cramer, S., Reddy, A., Minard, C., Voss, S., Fox, E., Liu, X., . . . Weigel, B. A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. Wiley.

Chicago Style (17th ed.) Citation

Cramer, Stuart L, Alyssa Terry Reddy, Charles Gene Minard, Stephan Voss, Elizabeth Fox, Xiaowei Liu, Kristina Denic, Joel M Reid, and Brenda J Weigel. A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. Wiley.

MLA (9th ed.) Citation

Cramer, Stuart L, et al. A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. Wiley.